Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting (NYSE:LLY)

INDIANAPOLIS, Feb. 28, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will highlight new Phase 3 data evaluating Taltz^® (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 75^th annual meeting of the American Academy of Dermatology (AAD), which will take place March 3-7, 2017, in Orlando, Fla.



Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting (NYSE:LLY)